VR Logo

Kura Oncology Inc. (KURA) download report


Healthcare | Biotechnology & Pharma Research

Kura Oncology Inc. (KURA) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States.

IPO Date: 22-Sep-2015

Chairman, CEO, Pres & Principal Financial Officer: Dr. Troy Edward Wilson J.D., Ph.D.

Chief Operating Officer: Ms. Kathleen Ford

Listing: NASDAQ: KURA

Country: United States

Headquarters: San Diego, CA

Website: https://kuraoncology.com

Key Facts

Market cap: $1,091.83 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-132.23 Mln

Cash: $480.08 Mln

Total Debt: $6.39 Mln

Insider's Holding: 2.78%

Liquidity: Low

52 Week range: $10.41 - 23.00

Shares outstanding: 66,636,100

10 Years Aggregate:

  • CFO: $-350.41 Mln
  • EBITDA: $-438.84 Mln
  • Net Profit: $-433.02 Mln

Stock Performance

Time Period Kura Oncology (KURA) S&P BSE Sensex S&P Small-Cap 600
YTD29.79-9.49-17.79
1 month42.51-2.87-2.72
3 months15.37-8.59-12.17
1 Year-15.090.81-15.82
3 Years-2.1410.397.14
5 Years18.2811.116.20
10 Years--12.0010.33
As on 24-Jun-2022
Year Kura Oncology (KURA) S&P Small-Cap 600 S&P BSE Sensex
2021-57.1325.2721.99
2020137.539.5715.75
2019-2.0720.8614.38
2018-8.19-9.705.87
2017159.3211.7327.91
2016-29.7624.741.95